Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Published in: American Journal of Cardiovascular Drugs 3/2002

01-05-2002 | Review Article

Naturoceutical Agents in the Management of Cardiovascular Disease

Author: Dr Denise D. Hermann

Published in: American Journal of Cardiovascular Drugs | Issue 3/2002

Login to get access

Abstract

During the past decade, complementary and alternative medicine (CAM) has grown in attractiveness to the Western public, and in recognition by practitioners of traditional medicine. The incorporation of effective CAM therapies into traditional practice is termed ‘integrative medicine’. One form of CAM demonstrating exponential growth through mass public consumerism is the use of naturoceuticals. Naturoceutical (or nutraceutical) agents are defined as mega-dose vitamins, herbal products or other ‘natural’ supplements purchased and consumed with premeditated ‘pharmaceutical’ intention to treat or prevent an illness or disease. Dietary supplements per se, are intended to supply adequate nutrients that may be lacking from the diet, and are thus, generally health promoting. A regulatory paradox exists since naturoceuticals are classified as dietary supplements although many possess measurable pharmacologic activity.
In reference to cardiovascular disorders, consumers use naturoceuticals for three distinctly recognizable purposes. These are the primary and secondary prevention of cardiovascular diseases and the treatment of diagnosed disorders such as heart failure, angina pectoris or arrhythmia. The evidence base supporting the routine use of naturoceutical products for these intentions is sparse, although the likelihood of harm from their consumption is low for an average, healthy adult. Evidence of significant harm (including fatalities) has been observed when certain herbal products are used in excess or in combination with, other herbs or prescription drugs. The safety of use at the extremes of age, or by persons with cardiac, renal or hepatic impairment is also a concern.
Healthcare professionals should routinely document patient naturoceutical use, be alert for and report suspected adverse effects. Until well-designed clinical trials determine the proper indication(s), dose safety profile and risk/benefit ratio for these products, their routine use should not be advocated. Thus, the role of naturoceutical agents in the integrative management of cardiovascular disorders remains undefined.
Footnotes
1
Use of a tradename is for product identification only and does not imply endorsement.
 
Literature
1.
Levitt, JA. Statement for the center for food safety and applied nutrition, Food and Drug Administration before the committee on government reform, US House of Representatives, March 20, 2001. Available at URL http://​www.​seniors.​gov/​articles/​0401/​dietary-supplements.​html.​ [Accessed 2002 Mar 6]
2.
Prevention Magazine’s Survey of consumer use of dietary supplements 1999/-2000. In: Prevention Magazine, Emmaus (PA): Rodale Press
3.
Taylor JM. Statement to the US Senate, Special Committee on Aging, Sep 10, 2001 [online]. Available from URL: http://​www.​fda.​gov/​ola/​2001/​health-fraud0910.​html.​ [Accessed 2001 Nov 20]
4.
Health Focus Specialty Market Research Report. The consumer market for heart health benefits. Atlanta, (GA), Health Focus International, 2001
5.
Greger JL. Dietary supplement use: consumer characteristics and interests. J Nutr 2001; 131: 1339S–43SPubMed
6.
Prevention’s International Survey on Wellness and consumer reaction to direct-to-consumer advertising of prescriptionmMedicines. In: Prevention Magazine, Emmaus (PA): Rodale Press, 2000/2001; 1: 1–71
7.
Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs and patterns of use. N Engl J Med 1993; 328: 246–52PubMedCrossRef
8.
Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280: 1569–75PubMedCrossRef
9.
Hermann DD, Kuiper JJ, Shabetai R, et al. Herbal, megavitamin and nutritional supplement use is very common in heart failure patient populations. J Am Coll Cardiol 1999; 33: 201A
10.
Ackman ML, Campbell JB, Buzak KA, et al. Use of nonprescription medications by patients with congestive heart failure. Ann Pharmacother 1999; 33: 674–9PubMedCrossRef
11.
Norred CL, Zamudio S, Palmer SK. Use of complementary and alternative medicines by surgical patients. AANA J 2000; 68(1): 13–8PubMed
12.
Foster DF, Phillips RS, Hamel MB, et al. Alternative medicine use in older Americans. J Am Geriatr Soc 2000; 48(12): 1560–5PubMed
13.
Palinkas LA, Kabongo ML. The use of complementary and alternative medicine by primary care patients. A SURF*NET study. J Fam Pract 2000 Dec; 49(12): 1121–30
14.
Johnson EM, Wootton JC, Kimzey R, et al. Use of herbal therapies by adults seen in an ambulatory care research setting: an exploratory survey. J Altern Complement Med 2000; 6(5): 429–35PubMedCrossRef
15.
Gulla J, Singer AJ. Use of alternative therapies among emergency department patients. Ann Emerg Med 2000; 35: 226–8PubMedCrossRef
16.
Klepser TB, Doucette WR, Horton MR, et al. Assessment of patients’ perceptions and beliefs regarding herbal therapies. Pharmacotherapy 2000; 20: 83–7PubMedCrossRef
17.
Astin, JA. Why patients use alternative medicine: results of a national study. JAMA 1998; 279: 1548–53PubMedCrossRef
18.
Planta M, Gundersen B, Petitt JC. Prevalence of the use of herbal products in a low-income population. Fam Med 2000; 32: 252–7PubMed
19.
Blendon RJ, DesRoches CM, Benson JM, et al. Americans’ views on the use and regulation of dietary supplements. Arch Intern Med 2001; 161: 805–10PubMedCrossRef
20.
Wootton JC, Sparber A. Surveys of complementary and alternative medicine (Pt I): feneral trends and demographic groups. J Altern Complement Med 2001; 7: 195–208PubMedCrossRef
21.
Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001; 135: 262–8PubMed
22.
Eisenberg DM, Kessler RC, Van Rompay MI, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001; 135: 344–51PubMed
23.
Srinivasan VS, Kucera P. Botanicals in the USP-NF. Pharmacopeial Forum 1998; 24: 6623–6
24.
Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001, 600
25.
Aronson JK. An account of the foxglove and its medicinal uses. 1785–1985, including a facsimile of the original monograph. London: Oxford University Press, 1985
26.
27.
Ritter G, Dembicki EL. The herbal history of digitalis: lessons for alternative medicine. JAMA 2000; 283: 884–5PubMedCrossRef
28.
Edmunds CW. The standardization of cardiac remedies. JAMA 1907; 48: 1744–7CrossRef
29.
Schwarz A. The standardization of digitalis. Am J Pharm 1934; 106: 196–210
30.
Lindenbaum J, Mellow MH, Blackstone MO, et al. Variation in biologic availability of digoxin from four preparations. N Engl J Med 1971; 285: 1344–7PubMedCrossRef
31.
32.
Marriott BM. A strategic plan for the Office of Dietary Supplements [online]. Jul 1998, National Institutes of Health, Bethesda, MD. Available from URL http://​ods.​od.​nih.​gov/​about/​plan.​html [ Accessed 2001 Nov 22]
33.
Food and Drug Administration. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Fed Regist 2000; 65: 1000–50
34.
Commission on Dietary Supplement Labels. Report to the president, the congress and the secretary of health and human services [online]. Nov 1997. Available from URL: http://​www.​web.​health.​gov/​dietsupp [Accessed 2001 Sep 2]
35.
Food and Drug Administration. Premarket notification for a new dietary ingredient. Fed Regist 1997; 62: 49886–92
36.
Food and Drug Administration. Current good manufacturing practice in manufacturing, packing, or holding dietary supplements. Fed Regist 1997; 5709
37.
ConsumerLab 2001 product quality data [online]. Available from URL: http://​www.​consumerlab.​com [Accessed 2002 Feb 6]
38.
Blumenthal M, Steele E. DSHEA at five years: a review of structure-function claims. HerbalGram 1999; 47: 38–9
39.
Hermann DD. Naturoceutical agents and cardiovascular medicine: the hope, hype and the harm. ACC Curr J Rev 1999; 8(5): 53–7CrossRef
40.
Angell M, Kassirer JP. Alternative medicine: the risks of untested and unregulated remedies. N Engl J Med 1998; 339: 839–41PubMedCrossRef
41.
Studdert DM, Eisenberg DM, Miller FH, et al. Medical malpractice implications of alternative medicine. JAMA 1998; 280: 1610–5PubMedCrossRef
42.
Kassirer JP. Adding insult to injury: usurping patients’ perogatives. N Engl J Med 1983; 308: 898–901PubMedCrossRef
43.
Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med 1998; 129: 1061–5PubMed
44.
Brauer BA. Herbal therapy: what a clinician needs to know to counsel patients effectively. Mayo Clin Proc 2000; 75: 835–41CrossRef
45.
Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med 1997; 127: 61–9PubMed
46.
Stupay S, Siversten L. Herbal and nutritional supplement use in the elderly. Nurse Pract 2000; 25: 56–68PubMedCrossRef
47.
Report 12 of the American Medical Association Council of Scientific Affairs. Altern Med. June 1997. Available from URL: http://​www.​ama-assn.​org/​ama-/​pub/​article/​2036-2523.​html [Accessed 2001 Mar 30]
48.
Howard BV, Kritchevsky D. Phytochemicals and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 95: 2591–3PubMedCrossRef
49.
Tribble DL, for the Nutrition Committee. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 99: 591–5PubMedCrossRef
50.
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2001; 38: 2102–13. Available from URL: www.​acc.​org/​clinical/​guidelines/​failure/​hfindex.​htm or www.americanheart.org/presenter.jhtml?identifier-11841 [Accessed 2002 Feb 6]
51.
Jaski ME, Schwartzberg JG, Guttman RA, et al. Medication review and documentation in physician office practice. Eff Clin Prac 2000; 3: 31–4
52.
Allen JM. Herbal medicines and dietary supplements. Skeptical Inquirer 2001; 25: 36–45
53.
Rotblatt M. Herbal medicine: a practical guide to safety and quality assurance. West J Med 1999; 171: 172–5PubMed
54.
Practice and Policy Guidelines Panel, National Institutes of Health, Office of Alternative Medicine. Clinical practice guidelines in complementary and alternative medicine. Arch Fam Med 1997; 6: 149–57CrossRef
55.
McKenna DJ, Jones K, Hughes K. Efficacy, safety and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001; 7: 70–90PubMed
56.
Greeson JM, Sanford B, Monti DA. St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological and clinical literature. Psychopharm (Berl) 2001; 153(4): 402–14CrossRef
57.
Pelton R. Drug-induced nutrient depletion handbook 1999v2000. Hudson (OH): Lexi-Comp, 1999
58.
The antioxidant vitamins A and C. Altern Med Alert 2000; 3 (12): S1-S2
59.
USFDA Center for Food Safety and Applied Nutrition. Illnesses and injuries associated with the use of selected dietary supplements 1993 [online]. Available from URL: http://​vm.​cfsan.​fda.​gov/​∼dms/​ds-ill.​html.​ [Accessed 2001 Nov 20]
60.
Specific vitamin deficiencies and toxicities. Available from URL: http://​www.​well-connected.​com/​report.​cgi/​doc39spec.​html [Accessed 2001 Jan 11]
61.
Institute of Medicine. Dietary reference intakes for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline: a report of the standing committee on the scientific evaluation of dietary reference intakes and its panel on folate, other B vitamins and choline and subcommittee on upper reference levels of nutrients, Food and Nutrition Board 1998. Washington, DC: National Academy Press, 1998
62.
National Research Council. Recommended Dietary Allowances. 10th ed. Report of the subcommittee on the tenth edition of the RDA. Food and Nutrition Board, Commission on Life Sciences, Washington, DC: National Academy Press, 1989: 344
63.
Renaud S, De Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1993; 339: 1523–6CrossRef
64.
Goldberg I, Mosca L, Paino MR, et al. Wine and your heart: a science advisory for healthcare professionals from the nutrition committee, council on epidemiology and prevention, and council on cardiovascular nursing of the American Heart Association. Circulation 2001; 103: 472–5PubMedCrossRef
65.
Pendurthi UR, Williams JT, Rao LVM. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler Thromb Vasc Biol 1999; 19: 419–26PubMedCrossRef
66.
Lonn EM, Yusuf S. Emerging approaches in cardiovascular prevention. In: Yusuf S, Cairns JA, Camm AJ, et al. editors. Evidence based cardiology. London: BMJ Books, 1998: 286–302
67.
Meagher E, Barry OP, Lawson JA, et al. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001; 285(9): 1178–82PubMedCrossRef
68.
Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–5PubMedCrossRef
69.
Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715–20PubMedCrossRef
70.
Hennekens CH, Burning JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145–9PubMedCrossRef
71.
Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of Vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781–6PubMedCrossRef
72.
Gissi-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447–55CrossRef
73.
The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154–60CrossRef
74.
Erdman, Jr JW. AHA science advisory: soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation. 2000; 102: 2555–9PubMedCrossRef
75.
Homocysteine Lowering Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894–8CrossRef
76.
Wald DS, Bishop L, Wald NJ, et al. Randomised trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001; 161: 695–700PubMedCrossRef
77.
78.
Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. Ann Int Med 2000; 133: 420–9PubMed
79.
Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism. JAMA 1998; 179: 1900–3CrossRef
80.
81.
Bordia A, Verma SK, Srivastava KC. Effect of garlic (allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1998 Apr; 58(4): 257–63PubMedCrossRef
82.
Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999; 69: 231–6PubMed
83.
Lyons AS, Petrucelli II, RJ, editors. Medicine: an illustrated history. 1st ed. New York: Abrams, 1978
84.
Morelli V, Zoorob RJ. Alternative therapies: Part II. Congestive heart failure and hypercholesterolemia. Am Fam Physician 2000; 62: 1325–30PubMed
85.
Blumenthal M, Busse WR, Goldberg A, et al. editors. The complete German commission e monographs: therapeutic guide to herbal medicines. Austin (TX): American Botanical Council, 1998
86.
PDR for Herbal Medicines. 2nd ed. Montevale (NJ): Medical Economics, 2000
87.
O’Hara MA, Kiefer D, Farrell K, et al. A review of 12 commonly used medicinal herbs. Arch Fam Med 1998; 7: 523–36PubMedCrossRef
88.
Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Arch Int Med 1998; 158: 2225–34CrossRef
89.
Morelli V, Zoorob RJ. Alternative therapies (Pt I): depression, diabetes, obesity. Am Fam Physician 2000; 62: 1051–60PubMed
90.
Meittenen TA, Puska P, Gulling H, et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308–12CrossRef
91.
Miller AL. Botanical influences on cardiovascular disease. Altern Med Rev 1998; 3: 422–31PubMed
92.
Gundling K, Ernst E. Complementary and alternative medicine in cardiovascular disease: what is the evidence it works? West J Med 1999; 171: 191–4PubMed
93.
Tran MT, Mitchell TM, Kennedy DT, et al. Role of coenzyme Q10 in chronic heart failure, angina and hypertension. Pharmacotherapy 2001; 21: 797–806PubMedCrossRef
94.
Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1998: 12; 347–353PubMedCrossRef
95.
Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of Coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999; 33: 1549–52PubMedCrossRef
96.
Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000; 57: 1221–30PubMed
97.
Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001; 142: E2–7PubMedCrossRef
98.
Joseph G, Zhao Y, Klaus W. Pharmacologic action profile of Crataegus extract in comparison to epinephrine, amrinone, milrinone and digoxin in the isolated perfused guinea pig heart. Arzneimeitte Forschung 1995; 45: 1261–5
99.
Rajendran S, Deepalakshmi PD, Parasakthy K, et al. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996; 123: 235–41PubMedCrossRef
100.
Holubarsch CJ, Colucci WS, Meinertz T, et al. Survival and prognosis: investigation of crataegus extract WS 1442 in congestive heart failure (SPICE): rationale, study design and study protocol. Eur J Heart Fail 2000; 2: 431–7PubMedCrossRef
101.
Boiling SF, Principal Investigator, US HERB-CHF Trial. Preliminary data presented at the American College of Cardiology 1st Annual Conference on the integration of complementary medicine in a traditional cardiology practice. 2001 Oct; 18–20; Santa Barbara
102.
Dwivedi S, Jauhari R. Beneficial effects of Terminalia ajuna in coronary artery disease. Indian Heart J 1997; 49: 507–10PubMed
103.
Sinclair S. Chinese herbs: a clinical review of astragalus, ligusticum and schizandrae. Altern Med Rev 1998; 3: 338–44PubMed
104.
Walli F, Grob PJ, Muller-Schoop J. Pseudo-(venocuran) lupus-a minor episode in the history of medicine. Schweiz Med Wochenschr 1981; 111: 1398–405PubMed
105.
Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency: a criteria-based systematic review. Arch Dermatol 1998; 134: 1356–60PubMedCrossRef
106.
Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: A meta-analysis of randomized trials. Am J Med 2000; 108: 276–81PubMedCrossRef
107.
Shulz V, Hansel R, Tyler VE, editors. Rational Phytotherapy: a physicians guide to herbal medicine. 3rd ed. Berlin: Springer-Verlag, 1998
108.
109.
110.
Rowen J, Lewis S. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46: 1775–6CrossRef
111.
Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50: 1933–44PubMedCrossRef
112.
De Leonardis V, Neri B, Baculli S, et al. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical trials. Int J Clin Pharmacol Res 1985; 5: 137–42PubMed
113.
Suzuki Y, Masumuro Y, Kobayashi A, et al. Myocardial carnitine deficiency in congestive heart failure. Lancet 1982; I: 116–7CrossRef
114.
Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997; 40: 265–86PubMedCrossRef
115.
Gurlek A, Tutar E, Akcil E, et al. The effects of L-carnitine treatment on left ventricular function and erythrocyte Superoxide dismutase activity in patients with ischemic cardiomyopathy. Eur J Heart Fail 2000; 2: 189–93PubMedCrossRef
116.
Gupta IR, Khan A, Hiremath S, et al. Does left ventricular function improve with L-carnitine after acute myocardial infarction? J Postgrad Med 1999; 45: 38–41PubMed
117.
The Investigators of the Study on Propionyl-L-Carnitine in Chronic Heart Failure. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 1999; 20: 70–6CrossRef
118.
Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998; 12: 291–9PubMedCrossRef
119.
Loster H, Miehe K, Punzel M, et al. Prolonged oral carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther 1999; 13: 537–46PubMedCrossRef
120.
Rizos, I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000; 139 (2 Pt 3): S 120–3CrossRef
121.
Drexler H, Zeiher AM, Meinzer K, et al. Correction of endothelial dysfunction in coronary artery microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546–50PubMedCrossRef
122.
Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336–44PubMedCrossRef
123.
Lerman A, Burnett Jr JC, Higano ST, et al. Long-term L-arginine supplementation improves small vessel coronary endothelial function in humans. Circulation 1998; 97: 2123–8PubMedCrossRef
124.
Bednarz B, Wolk R, Chamiec T, et al. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int J Cardiol 2000; 75: 205–10PubMedCrossRef
125.
Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-argninine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331–3PubMedCrossRef
126.
Walker HA, McGing E, Fisher I, et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001; 38: 499–502PubMedCrossRef
127.
Haller C, Andersen I, Kim S, et al. Evaluation of selected medical herbal references compared to published reports of adverse events related to common herbs. J Toxicol Clin Toxicol 2000; 38: 519–20
128.
Hendrich S, Fisher K. What do we need to know about active ingredients in dietary supplements?: summary of workshop discussion. J Nutr 2001; 131: 1387S–8SPubMed
129.
Blumenthal M. Interactions between herbs and conventional drugs: introductory considerations. HerbalGram 2000; 49: 53–63
130.
Montgomery A, Fox B. ANA Commentary on the 2001 Sep 10 GAO report on health products for seniors. JAMA 2001; 4: 1–3
131.
Ernst E. Herbal medicines: where is the evidence?. Growing evidence of effectiveness is counterbalanced by inadequate regulation. BMJ 2000; 321: 395–6PubMedCrossRef
132.
Markowitz JS. Screening herbs for drug interactions, [abstract of NCCAM grant #1R21AT000511-01]. Available from URL: http://​commons.​cit.​nih.​gov/​crisp3/​crisp_​lib [Accessed 2001 Nov 2]
133.
Shaw HS, Kroll DJ. The convergence of herb pharmacodynamics and herb-drug interactions on hemostasis. Altern Ther Health Med 2001; 7: 46–7PubMed
134.
Evans V. Herbs and the brain: friend or foe?.: the effects of ginkgo and garlic on warfarin use. J Neurosci Nurs 2000; 32: 228–32CrossRef
135.
136.
Heck AM, Dewitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. US Pharmacist 1998; 23: 83–6
137.
Yu CM, Chan JC, Sanderson JE. Chinese herbs and warfarin potentiation by Danshen. J Intern Med 1997; 241: 337–9PubMedCrossRef
138.
139.
Norred CL, Finlayson CA. Hemorrhage after the preoperative use of complementary and alternative medicines by surgical patients. AANA J 2000 Jun; 68(3): 217–20PubMed
140.
Norred CL, BrinkerF. Potential coagulation effects of preoperative complementary and alternative medicines. Altern Ther Health Med 2001; 7: 58–65PubMed
141.
Savar R, Kaye AD. Preanesthetic assessment, lesson 180: the patient on herbal medicines, Pt 1. Anesthesiology News 2000; 26: 44–8
142.
Blumental M, Goldberg A, Brinckmann J. Herbal medicine: expanded commission E monographs. 1st ed. Newton (MA): Integrative Medicine Communications, 2000
143.
Dickens P, Tai YT, But PPH, et al. Fatal accidental aconitine poisoning following ingestion of Chinese herbal medicine: a report of two cases. Forensic Sci Int 1994; 67: 55–8PubMedCrossRef
144.
Visudhiphan S, Poolsuppasit S, Piboonnukarintr O, et al. The relationship between high fibrinolytic activity and daily capsicum ingestion in Thais. Am J Clin Nutr 1982; 35: 1452–6PubMed
145.
Cruz L, Castaneda-Hernadez G, Navarete A, et al. Ingestion of chili pepper reduces salicylate bioavailability after oral aspirin administration in the rat. Can J Physiol Pharmacol 1999; 77: 441–6PubMed
146.
Homma M, Oka K, Ikeshima K, et al. Different effects of traditional Chinese medicines containing similar herbal constituentson prednisolone pharmacokinetics. J Pharm Pharmacol 1995; 47: 687–92PubMedCrossRef
147.
Lo AC, Chan K, Yeung GH, et al. The effects of Danshen (Salivia miltiorrhiza) on pharmacokinetics and pharmacodynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet 1992; 56: 257–62CrossRef
148.
Losche W, Mazurov AV, Heptinstall S, et al. An extract of Feverfew inhibits the interaction of human platelets with collagen substrates. Thromb Res 1987; 48: 511–8PubMedCrossRef
149.
Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in Feverfew. J Pharm Pharmacol 1988; 40: 743–5PubMedCrossRef
150.
Barrett B, Keifer D, Rabago D. Assessing the risks and benefits of herbal medicine: an overview of scientific evidence. Altern Ther 1999; 5: 40–9
151.
Muller JL, Clauson KA. Pharmaceutical considerations of common herbal medicine. Am J Manag Care 1997; 3: 1753–70
152.
Bracken J. Ginger as an antiemetic: possible side effects due to its thromboxane synthetase activity. Anaesthesia 1991; 46: 705–6
153.
Attele AS, Wu HA, Yuan CS. Ginseng pharmacology: multiple constituents and multiples actions. Biochem Pharmacol 1999; 58: 1685–93PubMedCrossRef
154.
Becker BN, Greene J, Evanson J, et al. Ginseng-induced diuretic resistance. JAMA 1996; 276: 606–7PubMedCrossRef
155.
Bucci LR. Selected herbals and human exercise performance. Am J Clin Nutr 2000; 72 Suppl. 2: 624S–36SPubMed
156.
Kuo SC, Teng CM, Lee JC, et al. Antiplatelet components in Panax ginseng. Planta Med 1990; 56: 164–7PubMedCrossRef
157.
Lee FC, Ko JH, Park JK, et al. Effects of Panax ginseng on blood alcohol clearance in man. Clin Exp Pharmacol Physiol 1987; 14: 543–6PubMedCrossRef
158.
Siegl RK. Ginseng abuse syndrome: problems with the panacea. JAMA 1979; 241: 1614–5CrossRef
159.
Wu W, Zhang XM, Liu PM, et al. Effects of Panax notoginseng saponin Rgl on cardiac electrophysiological properties and ventricular fibrillation threshold in dogs. Zhongguo Yao Li Xue Bao 1995; 16(5): 459–63PubMed
160.
Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng: a systematic review of randomized clinical trials. Eur J Clin Pharmacol 1999; 55: 567–75PubMedCrossRef
161.
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54: 692–3PubMed
162.
Schlegelmilch R, Heywood R. Toxicity of crataegus (hawthorn) extract (WS 1442). J Am Coll Toxicol 1994; 113: 103–11CrossRef
163.
Yun-Choi HS, Kim JH, Lee P. Potential inhibitors of platelet aggregation from plant sources III. J Nat Prod 1987; 50: 1059–63PubMedCrossRef
164.
Bohn B, Nebe CR, Birr C. Flow-cytometric studies with Eleutherococcus senticosus extract as an immunomodulatory agent. Arzneimittel Forschung (Drug Res) 1987; 37: 1193–6
165.
Hikino H, Takahashi M, Otake K, et al. Isolation and hypoglycemic activity of A, B, C, D, E, F and G: glycans of Eleutherococcus senticosus roots. J Nat Prod 1986; 49: 293–7PubMedCrossRef
166.
Chan MY. The effect of berberine on bilirubin excretion in the rat. Comp Med East West 1977; 5: 161–8PubMed
167.
Hui K, Yu J, Chan W, et al. Interaction of berberine with human platelet alpha 2 adrenoreceptors. Life Sci 1991; 49: 315–24PubMedCrossRef
168.
Preininger V. The pharmacology and toxicology of the papaveraceae alkaloids. In: Manske RHF, Holmes HL, editors. The alkaloids. New York: Academic Press, 1975: 239
169.
Jones WK. Public meeting transcript. Safety of dietary supplements containing ephedrine alkaloids: US food and drug administration, center for food safety and applied nutrition. Aug 2000. Available from URL: http://​www.​fds.​gov [Accessed 2001 Oct 10]
170.
Schussler M, Holzl J, Frike U. Myocardial effects of flavonoids from Crataegus species. Arzneimittel Forschung 1995; 45: 842–5PubMed
171.
Lei ZY, Qin H, Liao JZ. Action of astralgus membranecus on left ventricular function of angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994; 14: 199–202PubMed
172.
Ma J, Peng A, Lin S. Mechanisms of the therapeutic effect of astralgus membranaceus on sodium and water retention in experimental heart failure. Chin Med J 1998; 111: 17–23PubMed
173.
Li SQ, Yuan RX, Gao H. Clinical observation on the treatment of ischemic heart disease with astralgus membraneceus. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995; 15: 77–80PubMed
174.
Peng T, Yang Y, Riesemann H, et al. The inhibitory effect of astralgus membranaceus on coxsackie B-3 virus RNA replication. Chin Med Sci J 1995; 10: 146–50PubMed
175.
Zhang WJ, Wojta J, Binder BR. Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression. J Vasc Res 1997; 34: 273–80PubMedCrossRef
176.
Samenuk D, Link MS, Contreras R, et al. Adverse cardiovascular events associated with nutritional supplements containing ma huang (ephedra). J Am Coll Cardiol 1999; 33 Suppl. 1: 117A
177.
Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedrine alkaloids. N Engl J Med 2000; 343(25): 1833–8PubMedCrossRef
178.
Ko R. Adverse reactions to watch for in patients using herbal remedies. West J Med 1999; 17: 181–6
179.
Geopel M, Hecker U, Krege S, et al. Saw Palmetto extracts potently and non-competitively inhibit human alpha1-adrenoreceptors in vitro. Prostate 1999; 38: 208–15CrossRef
180.
Plosker GL, Brogden RN. Serenoa repens (Permixon R): a review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996; 9: 379–95PubMedCrossRef
181.
Tuncok Y, Kozan O, Cavdar C, et al. Urginea maritima (squill) toxicity. J Toxicol Clin Toxicol 1995; 33: 83–6PubMedCrossRef
182.
Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 1998; 31 Suppl. 1: 16–21PubMedCrossRef
183.
Lantz MS, Buchalter E, Giambanco V. St John’s Wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 2: 7–10CrossRef
184.
Miller LG. Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158: 2200–11PubMedCrossRef
185.
Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s Wort. Lancet 2000; 355: 548–9PubMedCrossRef
186.
Piscatelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John’s Wort. Lancet 2000; 355: 547–8CrossRef
187.
Andreas J, Brockemoller J, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s Wort. Clin Pharmacol Ther 1999; 66: 338–45CrossRef
188.
Nebel A, Schneider BJ, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort. Clin Pharmacol Ther 1999; 66: 338–45CrossRef
189.
Cowan RA, Hartneil G, Lowdell C, et al. Metabolic acidosis induced by carvonic anhydrase inhibitors and salicylates in patients with normal renal function. BMJ 1984; 289: 347–8PubMedCrossRef
190.
Furst DE, Sarkissian E, Blocka K, et al. Serum concentrations of salicylate and naproxen during concurrent therapy in patients with rheumatoid arthritis. Arthritis Rheum 1987; 30: 1157–62PubMedCrossRef
191.
Gear RW, Gordon NC, Heller PH, et al. Enhancement of morphine analgesia by the alpha 2-adrenergic antagonist yohimbine. Neuroscience 1995; 66: 1–5CrossRef
192.
Liu N, Bonnet F, Delaunay L, et al. Partial reversal of the effects of extradural clonidine by oral yohimbine in postoperative patients. Br J Anaesth 1993; 70: 515–8PubMedCrossRef
193.
Musson NR, Vergassola C, Pende A, et al. Yohimbine effects on blood pressure and plasma catecholamines in human hypertension. Am J Hypertens 1995; 8: 565–71CrossRef
194.
DeSmet PAGM. Yohimbine alkaloids: general discussion. In: DeSmets PAGM, Keller K, Hansel R, Chandler RF editors. Adverse effects of herbal drugs. Vol 3. Berlin: Springer, 1997: 181–206CrossRef
195.
Metadata
Title
Naturoceutical Agents in the Management of Cardiovascular Disease
Author
Dr Denise D. Hermann
Publication date
01-05-2002
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 3/2002
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.2165/00129784-200202030-00005

Other articles of this Issue 3/2002

American Journal of Cardiovascular Drugs 3/2002 Go to the issue

Leading Article

Cardiovascular Risk in Patients with Early Renal Insufficiency

Leading Article

Perspectives of Drug-Eluting Stents

Review Article

Laser Coronary Angioplasty

Current Opinion

Can Angiotensin Receptor Antagonists Prevent Restenosis After Stent Placement?

OriginalPaper

Opinion and Evidence in Cardiovascular Therapeutics

Leading Article

Effects of the Thiazolidinediones on Cardiovascular Risk Factors